Compare Recursion Pharmaceuticals Inc (RXRX) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United States Oil ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B), while United States Oil ETF trades at $146.55 (market cap $1.83B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and United States Oil ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and United States Oil ETF for 21 Days on average.
| RXRX | USO | |
|---|---|---|
Market Cap | $2.31B | $1.83B |
Volume | 40,478,768 | 3,073,172 |
Sector | Health | — |
52-Week High | $6.79 | $161.86 |
52-Week Low | $2.84 | $66.17 |
Typical Hold Time | 22 Days | 21 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
USO trades at $143.91, down 0.7% amid mixed oil market signals. Technical indicators show neutral momentum with bearish moving averages, while geopolitical tensions and supply dynamics dominate sentiment. The stock faces resistance at $145 and support at $142, with recent news highlighting Middle East conflicts and OPEC+ production decisions affecting energy sector volatility.
The outlook remains uncertain with competing pressures from geopolitical risks and coordinated reserve releases. Investment opportunities exist if supply disruptions persist, but risks include potential price stabilization from G-7 interventions and broader market volatility. Current technical positioning suggests cautious near-term trading with key levels defining directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
